Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer
From MaRDI portal
Publication:827694
DOI10.1016/j.jtbi.2020.110403zbMath1455.92069arXiv2001.10573OpenAlexW3042640655WikidataQ97640469 ScholiaQ97640469MaRDI QIDQ827694
Heyrim Cho, Doron Levy, Zuping Wang
Publication date: 13 January 2021
Published in: Journal of Theoretical Biology (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/2001.10573
Related Items (1)
Cites Work
- Mathematical model creation for cancer chemo-immunotherapy
- Metamodeling tumor-immune system interaction, tumor evasion and immunotherapy
- Modeling immunotherapy of the tumor -- immune interaction
- Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis
- The dynamics of an optimally controlled tumor model: A case study
- A time delay model of tumour-immune system interactions: global dynamics, parameter estimation, sensitivity analysis
- Ordinary differential equation models for adoptive immunotherapy
- Mathematical model of chimeric anti-gene receptor (CAR) T cell therapy with presence of cytokine
- Behavior of tumors under nonstationary therapy
- Optimal control of tumour-immune model with time-delay and immuno-chemotherapy
- A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction
- Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations
- An immune system-tumour interactions model with discrete time delay: model analysis and validation
- Cancer immunotherapy, mathematical modeling and optimal control
- Chemotherapy for tumors: An analysis of the dynamics and a study of quadratic and linear optimal controls
This page was built for publication: Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer
